Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
McGill University
$105,000.00
Neuroanatomical, Network, and Cognitive Changes Associated with Clinical and Pharmacological Outcome in First Episode Psychosis: A Longitudinal Study
EF 2016-17
Résumé
Individuals experiencing a first episode of psychosis are faced with a critical transition point in their mental health, accompanied by profound changes in cognition, behaviour, and overall well-being. Available antipsychotic medications provide relief of positive symptoms (e.g., hallucinations, delusions, grandiose thoughts), but do not target other more pressing symptom constructs characterizing schizophrenia, namely negative symptoms (e.g., flat affect, amotivation, anhedonia), and cognitive deficits (e.g., executive dysfunction, verbal memory problems). However, one antipsychotic, aripiprazole (brand name "Abilify"), holds promise due to its links with hippocampal neurogenesis and improvements in verbal memory performance. No study to date has looked carefully at the effects of Abilify across cognitive, neuroanatomical, brain network, and clinical domains in a sample of early psychosis patients. More importantly, our research aims to examine this cohort using a high-resolution multi-modal imaging approach over time, and link progressive changes at the neural level to reliable cognitive and clinical outcome measures. There is strong evidence to suggest that Abilify has a pro-cognitive capacity. If this proves true and coincides with measures obtained through neuroimaging, our current research will unquestionably facilitate the use of this antipsychotic for enhancement of cognitive dysfunction, especially verbal memory deficits, in first episode psychosis. Understanding early psychosis and optimal pharmacological and cognitive treatments through the bridging of neuroimaging and clinical outcome will provide a valuable component to the field of translational psychiatry, and will enhance the integration of neuroimaging within clinical platforms for future endeavours.
Programme
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
365425
Name
Makowski Carolina
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Clinical
Prcname2
Doctoral Research Awards - B
Projecttitle
Neuroanatomical, Network, and Cognitive Changes Associated with Clinical and Pharmacological Outcome in First Episode Psychosis: A Longitudinal Study
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Aripiprazole; Brain Connectivity; Clinical Outcome; First Episode Psychosis; Hippocampus; Negative Symptoms; Neuroimaging; Verbal Memory
Abstract
Individuals experiencing a first episode of psychosis are faced with a critical transition point in their mental health, accompanied by profound changes in cognition, behaviour, and overall well-being. Available antipsychotic medications provide relief of positive symptoms (e.g., hallucinations, delusions, grandiose thoughts), but do not target other more pressing symptom constructs characterizing schizophrenia, namely negative symptoms (e.g., flat affect, amotivation, anhedonia), and cognitive deficits (e.g., executive dysfunction, verbal memory problems). However, one antipsychotic, aripiprazole (brand name "Abilify"), holds promise due to its links with hippocampal neurogenesis and improvements in verbal memory performance. No study to date has looked carefully at the effects of Abilify across cognitive, neuroanatomical, brain network, and clinical domains in a sample of early psychosis patients. More importantly, our research aims to examine this cohort using a high-resolution multi-modal imaging approach over time, and link progressive changes at the neural level to reliable cognitive and clinical outcome measures. There is strong evidence to suggest that Abilify has a pro-cognitive capacity. If this proves true and coincides with measures obtained through neuroimaging, our current research will unquestionably facilitate the use of this antipsychotic for enhancement of cognitive dysfunction, especially verbal memory deficits, in first episode psychosis. Understanding early psychosis and optimal pharmacological and cognitive treatments through the bridging of neuroimaging and clinical outcome will provide a valuable component to the field of translational psychiatry, and will enhance the integration of neuroimaging within clinical platforms for future endeavours.
Competitiondate
201610
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Makowski, Carolina
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~